{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-255185","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.178616+00:00","generated_at":"2026-05-30T02:00:00.520411+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ARS Pharma licenses neffy to ALK for $145M upfront; up to $320M milestones","bullets":["Upfront $145M from ALK; regulatory/commercial milestones up to $20M and sales milestones up to $300M.","Exclusive license for epinephrine nasal spray (neffy) outside US, Japan, China, Australia, New Zealand for all human uses.","Tiered royalties in mid-to-high teens on net sales; ARS supplies product for first 5 years under supply agreement.","ALK must use commercially reasonable efforts for regulatory approval and commercialization; ARS may terminate if ALK sells competing non-injectable epinephrine in US.","Deal covers anaphylaxis and Type I allergic reactions; parties may agree on future indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-255185","json":"https://secwatch.observer/filing/0001193125-24-255185.json","markdown":"https://secwatch.observer/filing/0001193125-24-255185.md","text":"https://secwatch.observer/filing/0001193125-24-255185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312524255185/0001193125-24-255185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312524255185/d810986d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:00:00.520411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}